BRPI0406678A - Método para produzir proteìnas policlonais recombinantes - Google Patents
Método para produzir proteìnas policlonais recombinantesInfo
- Publication number
- BRPI0406678A BRPI0406678A BR0406678-2A BRPI0406678A BRPI0406678A BR PI0406678 A BRPI0406678 A BR PI0406678A BR PI0406678 A BRPI0406678 A BR PI0406678A BR PI0406678 A BRPI0406678 A BR PI0406678A
- Authority
- BR
- Brazil
- Prior art keywords
- cells
- collection
- library
- nucleic acid
- recombinant polyclonal
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1093—General methods of preparing gene libraries, not provided for in other subgroups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
- C40B50/06—Biochemical methods, e.g. using enzymes or whole viable microorganisms
Abstract
"MéTODO PARA PRODUZIR PROTEìNAS POLICLONAIS RECOMBINANTES". A presente invenção refere-se a um método para a produção de uma composição de proteína policlonal recombinante, particularmente uma composição de anticorpo policlonal recombinante. O método compreende obter uma coleção de células transfectadas com uma biblioteca de seq³ências de ácidos nucléicos variantes, em que cada célula na coleção é transfectada com e capaz de expressar um membro da biblioteca, que codifica um membro distinto de uma proteína policional que liga um antígeno particular e que está localizada no mesmo sítio único no genoma das células individuais na referida coleção, em que a referida seq³ência de ácido nucléico não é naturalmente associada com a referida célula na coleção. As células são cultivadas sob condições apropriadas para expressão da proteína policional, que é obtida a partir das células ou sobrenadante de cultura. A seq³ência de ácido nucléico é introduzida nas células por transfecção com uma biblioteca de vetores para a integração específica para sítio. O presente método é apropriado para a produção de anticorpos policionais recombinantes, assim tornando disponível uma substituição superior de produtos de imunoglobulinas terapêuticos derivados de plasma.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43840303P | 2003-01-07 | 2003-01-07 | |
DKPA200300008 | 2003-01-07 | ||
US47601803P | 2003-06-05 | 2003-06-05 | |
PCT/DK2004/000001 WO2004061104A2 (en) | 2003-01-07 | 2004-01-07 | Method for manufacturing recombinant polyclonal proteins |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0406678A true BRPI0406678A (pt) | 2005-12-20 |
Family
ID=32718469
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0406678-2A BRPI0406678A (pt) | 2003-01-07 | 2004-01-07 | Método para produzir proteìnas policlonais recombinantes |
Country Status (19)
Country | Link |
---|---|
US (1) | US9163232B2 (pt) |
EP (2) | EP1583830B1 (pt) |
JP (2) | JP4589914B2 (pt) |
KR (1) | KR101024443B1 (pt) |
AT (1) | ATE338816T1 (pt) |
AU (1) | AU2004203727C1 (pt) |
BR (1) | BRPI0406678A (pt) |
CA (1) | CA2512647C (pt) |
DE (1) | DE602004002275T2 (pt) |
DK (1) | DK1583830T3 (pt) |
EA (1) | EA013225B1 (pt) |
ES (1) | ES2273202T3 (pt) |
HK (1) | HK1078896A1 (pt) |
IL (1) | IL169101A (pt) |
MX (1) | MXPA05006724A (pt) |
NZ (1) | NZ541458A (pt) |
PT (1) | PT1583830E (pt) |
SI (1) | SI1583830T1 (pt) |
WO (1) | WO2004061104A2 (pt) |
Families Citing this family (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE47770E1 (en) | 2002-07-18 | 2019-12-17 | Merus N.V. | Recombinant production of mixtures of antibodies |
ES2442615T5 (es) | 2002-07-18 | 2023-03-16 | Merus Nv | Producción recombinante de mezclas de anticuerpos |
PT1583830E (pt) | 2003-01-07 | 2006-11-30 | Symphogen As | Método para produzir proteínas policlonais recombinantes |
TWI333977B (en) | 2003-09-18 | 2010-12-01 | Symphogen As | Method for linking sequences of interest |
KR101319848B1 (ko) | 2004-07-20 | 2013-10-18 | 심포젠 에이/에스 | 재조합 폴리클로날 단백질 또는 폴리클로날 세포주의구조적 특성화 방법 |
AU2005263331B8 (en) | 2004-07-20 | 2011-06-16 | Symphogen A/S | Anti-Rhesus D recombinant polyclonal antibody and methods of manufacture |
JP4856177B2 (ja) | 2005-06-24 | 2012-01-18 | ユニジーン・ラボラトリーズ・インコーポレーテッド | アミド化生成物の調製に有用な酵素を発現させるための細胞株 |
US7850965B2 (en) | 2005-12-05 | 2010-12-14 | Symphogen A/S | Anti-orthopoxvirus recombinant polyclonal antibody |
WO2007101441A1 (en) * | 2006-03-06 | 2007-09-13 | Symphogen A/S | Recombinant polyclonal antibody for treatment of respiratory syncytial virus infections |
US7504106B2 (en) | 2006-03-14 | 2009-03-17 | Boris Skurkovich | Method and composition for treatment of renal failure with antibodies and their equivalents as partial or complete replacement for dialysis |
FR2910490B1 (fr) * | 2006-12-20 | 2012-10-26 | Lab Francais Du Fractionnement | Lignee cellulaire a forte activite transcriptionnelle pour la production de proteines, notamment therapeutiques |
US10155038B2 (en) | 2007-02-02 | 2018-12-18 | Yale University | Cells prepared by transient transfection and methods of use thereof |
WO2008097926A2 (en) * | 2007-02-02 | 2008-08-14 | Yale University | Transient transfection with rna |
US9249423B2 (en) | 2007-02-02 | 2016-02-02 | Yale University | Method of de-differentiating and re-differentiating somatic cells using RNA |
TW200846362A (en) * | 2007-02-09 | 2008-12-01 | Symphogen As | A polyclonal antibody product |
NZ578851A (en) | 2007-03-01 | 2011-09-30 | Symphogen As | Method for cloning cognate antibodies |
ES2582386T3 (es) | 2007-03-01 | 2016-09-12 | Symphogen A/S | Composiciones de anticuerpos recombinantes contra el receptor del factor de crecimiento epidérmico |
EP2134747A2 (en) * | 2007-03-06 | 2009-12-23 | Symphogen A/S | Recombinant antibodies for treatment of respiratory syncytial virus infections |
JP5941616B2 (ja) * | 2007-05-25 | 2016-06-29 | シムフォゲン・アクティーゼルスカブSymphogen A/S | 組み換えポリクローナルタンパク質を製造する方法 |
EP2199390B1 (en) | 2007-08-30 | 2016-12-21 | Daiichi Sankyo Company, Limited | Anti-epha2 antibody |
EP2244735A4 (en) | 2007-10-02 | 2011-02-23 | Avaxia Biologics Inc | ANTIBODY THERAPY FOR USE IN THE DIGESTIVE TUBE |
WO2009048072A1 (ja) | 2007-10-11 | 2009-04-16 | Daiichi Sankyo Company, Limited | 破骨細胞関連蛋白質Siglec-15を標的とした抗体 |
JP2011518790A (ja) * | 2008-04-23 | 2011-06-30 | シムフォゲン・アクティーゼルスカブ | ポリクローナルタンパク質を製造する方法 |
CN102137874B (zh) | 2008-08-29 | 2015-02-18 | 西福根有限公司 | 抗表皮生长因子受体的重组抗体组合物 |
BRPI0917352A2 (pt) * | 2008-08-29 | 2017-08-22 | Symphogen As | Métodos para produção de uma biblioteca de pares cognatos que compreende sequências ligadas que codificam regiões variáveis e para gerar um vetor que codifica um anticorpo quimérico com regiões de seres humanos constantes e regiões variáveis não humanas, biblioteca de vetores, e método para produção de uma biblioteca de sequências de imunoglobulina derivadas de aves |
KR101690340B1 (ko) | 2009-04-09 | 2016-12-27 | 다이이찌 산쿄 가부시키가이샤 | 항 Siglec-15 항체 |
ES2547872T3 (es) | 2009-10-15 | 2015-10-09 | Avaxia Biologics, Inc. | Agentes terapéuticos de anticuerpos con actividad local en el tracto digestivo |
BR112013010574A2 (pt) | 2010-10-29 | 2016-08-09 | Daiichi Sankyo Co Ltd | anticorpo, fragmento funcional do anticorpo, composição farmacêutica, usos de um anticorpo ou um fragmento funcional do mesmo e de pelo menos um membro selecionado do grupo que consiste de paclitaxel, carvoplatina, cpt-11, vinblastina, e 5-fu, polinucleotídeo, vetor, célula hospedeira transformada, e, método de produzir o anticorpo |
WO2012059858A1 (en) | 2010-11-01 | 2012-05-10 | Symphogen A/S | Anti-her3 antibodies and compositions |
EP2640743B1 (en) | 2010-11-16 | 2016-10-05 | Excelimmune, Inc. | Methods for producing recombinant proteins |
RS57279B1 (sr) | 2011-04-25 | 2018-08-31 | Daiichi Sankyo Co Ltd | Anti-b7-h3 antitelo |
SI2794878T1 (sl) | 2011-12-22 | 2020-07-31 | F. Hoffmann-La Roche Ag | Organizacija ekspresijskega vektorja, postopki izdelave nove proizvodne celice in njihova uporaba za rekombinantno proizvodnjo polipeptidov |
GB2502127A (en) | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
CA2868959A1 (en) | 2012-03-30 | 2013-10-03 | Daiichi Sankyo Company, Limited | Cdr-modified anti-siglec-15 antibody |
CA2868965A1 (en) | 2012-03-30 | 2013-10-03 | Daiichi Sankyo Company, Limited | Anti-siglec-15 antibody |
US9714298B2 (en) | 2012-04-09 | 2017-07-25 | Daiichi Sankyo Company, Limited | Anti-FGFR2 antibodies and methods of use thereof for treating cancer |
NZ630551A (en) | 2012-04-20 | 2017-11-24 | Merus Nv | Methods and means for the production of ig-like molecules |
PL2841457T3 (pl) | 2012-04-27 | 2019-09-30 | Daiichi Sankyo Company, Limited | Przeciwciało anty-ROBO4 |
EP2844675B1 (en) | 2012-05-02 | 2019-01-02 | Symphogen A/S | Humanized pan-her antibody compositions |
JP2015163047A (ja) * | 2012-06-20 | 2015-09-10 | 国立大学法人 東京大学 | タンパク質の迅速改良法 |
AU2013285355A1 (en) | 2012-07-06 | 2015-01-29 | Genmab B.V. | Dimeric protein with triple mutations |
NZ630563A (en) | 2012-09-27 | 2017-04-28 | Merus Nv | Bispecific igg antibodies as t cell engagers |
EP2953970A4 (en) | 2013-02-08 | 2016-06-29 | Misfolding Diagnostics Inc | TRANSTYRETIN ANTIBODIES AND USES THEREOF |
JP6494519B6 (ja) | 2013-09-30 | 2019-07-31 | 第一三共株式会社 | 抗lps o11抗体 |
JP6509735B2 (ja) | 2013-10-08 | 2019-05-08 | 第一三共株式会社 | 抗fgfr2抗体と他剤の組合せ |
WO2015093925A1 (es) * | 2013-12-19 | 2015-06-25 | CASTRO ALDRETE, Jorge Isaac | Método de producción de anticuerpos específicos |
RS61129B1 (sr) | 2014-02-28 | 2020-12-31 | Merus Nv | Antitelo koje vezuje erbb-2 i erbb-3 |
US10844127B2 (en) | 2014-02-28 | 2020-11-24 | Merus N.V. | Antibodies that bind EGFR and ErbB3 |
IL250902B (en) | 2014-09-16 | 2022-08-01 | Symphogen As | Anti-met antibodies and preparations |
JP2018518152A (ja) | 2015-03-27 | 2018-07-12 | ユニバーシティ オブ サザン カリフォルニア | 充実性腫瘍を処置するためのlhrに指向されたcar t細胞治療 |
WO2016197064A1 (en) | 2015-06-04 | 2016-12-08 | Epstein Alan L | Lym-1 and lym-2 targeted car cell immunotherapy |
LT3115376T (lt) | 2015-07-10 | 2018-11-12 | Merus N.V. | Antikūnai, kurie jungiasi su žmogaus cd3 |
CN109310744A (zh) | 2015-09-23 | 2019-02-05 | 赛通免疫有限责任公司 | 用于免疫治疗的flt3定向car细胞 |
FI3354729T3 (fi) | 2015-09-24 | 2024-04-23 | Daiichi Sankyo Co Ltd | Anti-garp-vasta-aine |
MX2018004988A (es) | 2015-10-23 | 2018-11-09 | Merus Nv | Moleculas de union que inhibe el crecimiento de cancer. |
WO2017205014A1 (en) * | 2016-05-26 | 2017-11-30 | Qilu Puget Sound Biotherapeutics Corporation | Mixtures of antibodies |
IL267567B1 (en) | 2016-12-22 | 2024-04-01 | Daiichi Sankyo Co Ltd | Anti-CD3 antibody - for use in treating or preventing cancer and molecules containing the antibody |
KR20190133160A (ko) | 2017-02-07 | 2019-12-02 | 다이이찌 산쿄 가부시키가이샤 | 항-gprc5d 항체 및 항-gprc5d 항체를 포함하는 분자 |
TWI782000B (zh) | 2017-03-30 | 2022-11-01 | 日商第一三共股份有限公司 | 抗gpr20抗體、其製造方法及其應用 |
BR112019020508A2 (pt) | 2017-03-31 | 2020-08-04 | Merus N.V. | anticorpos biespecíficos de ligação a erbb-2 e erbb3 para utilização no tratamento de células que possuem um gene de fusão nrg1 |
CA3185303A1 (en) | 2017-04-05 | 2018-10-11 | Symphogen A/S | Combination therapies targeting pd-a, tim-3, and lag-3 |
CN110913905A (zh) | 2017-06-30 | 2020-03-24 | 国立大学法人北海道大学 | 不产生生长障碍的小儿骨质疏松症治疗药 |
TW202402805A (zh) | 2017-07-27 | 2024-01-16 | 日商第一三共股份有限公司 | 抗cd147抗體、醫藥組成物、該等之用途及抗cd147抗體之製造方法 |
JP2020530028A (ja) | 2017-08-09 | 2020-10-15 | メルス ナムローゼ フェンノートシャップ | EGFR及びcMETに結合する抗体 |
JP7384668B2 (ja) | 2017-10-05 | 2023-11-21 | 第一三共株式会社 | 細胞傷害性t細胞枯渇用組成物 |
US11795579B2 (en) | 2017-12-11 | 2023-10-24 | Abalone Bio, Inc. | Yeast display of proteins in the periplasmic space |
KR20200128017A (ko) | 2018-03-05 | 2020-11-11 | 각코우호우징 사이타마이카다이가쿠 | 이소성 골화의 치료 또는 예방을 위한 의약 조성물 |
KR20210018192A (ko) | 2018-05-31 | 2021-02-17 | 다이이찌 산쿄 가부시키가이샤 | 항인간 tlr7 항체 |
SG11202012713RA (en) | 2018-06-22 | 2021-01-28 | Genmab As | Method for producing a controlled mixture of two or more different antibodies |
CN112673023B (zh) | 2018-07-10 | 2023-09-12 | 国立大学法人神户大学 | 抗SIRPα抗体 |
JP7406488B2 (ja) | 2018-07-27 | 2023-12-27 | 第一三共株式会社 | 抗体-薬物コンジュゲートの薬物部位を認識する蛋白質 |
JPWO2021020282A1 (pt) | 2019-07-26 | 2021-02-04 | ||
BR112022007632A2 (pt) | 2019-10-25 | 2022-07-12 | Daiichi Sankyo Co Ltd | Composição farmacêutica e preparação de kit para tratamento de câncer, e, métodos para tratamento de câncer e de um paciente com câncer |
US20240042002A1 (en) | 2019-12-31 | 2024-02-08 | Antagonis | Compositions and methods for the prevention of S. aureus infection |
CA3177152A1 (en) | 2020-06-12 | 2021-12-16 | David Scott Johnson | Recombinant polyclonal proteins targeting covid-19 and methods of use thereof |
WO2022031834A1 (en) | 2020-08-05 | 2022-02-10 | Gigagen, Inc. | Recombinant polyclonal proteins targeting zika and methods of use thereof |
US11975066B2 (en) | 2020-08-31 | 2024-05-07 | SAB Biotherapeutics, Inc. | Ungulate-derived polyclonal immunoglobulin specific for coronavirus protein and uses thereof |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US155114A (en) * | 1874-09-15 | Improvement in methods of laying and forming cast-iron pipes | ||
CA1293460C (en) * | 1985-10-07 | 1991-12-24 | Brian Lee Sauer | Site-specific recombination of dna in yeast |
WO1991016074A1 (en) | 1990-04-19 | 1991-10-31 | Medimmune, Inc. | Administration of monoclonal antibodies against respiratory viruses |
GB9022543D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Antibody production |
WO1992015694A1 (en) | 1991-03-08 | 1992-09-17 | The Salk Institute For Biological Studies | Flp-mediated gene modification in mammalian cells, and compositions and cells useful therefor |
PT1231268E (pt) * | 1994-01-31 | 2005-11-30 | Univ Boston | Bancos de anticorpos policlonais |
US6111166A (en) | 1994-09-19 | 2000-08-29 | Medarex, Incorporated | Transgenic mice expressing human Fcα and β receptors |
GB9703369D0 (en) | 1997-02-18 | 1997-04-09 | Lindqvist Bjorn H | Process |
EP0981637B1 (en) * | 1997-03-14 | 2005-05-25 | Biogen Idec Inc. | Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same |
US6368821B1 (en) | 1997-04-14 | 2002-04-09 | Stratagene | Process for infecting eukaryotic cells with a bacterial virus |
AU5898599A (en) * | 1998-08-19 | 2000-03-14 | Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for genomic modification |
US20020155114A1 (en) | 1998-08-31 | 2002-10-24 | James D. Marks | Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins |
AU781628B2 (en) | 1999-07-14 | 2005-06-02 | Clontech Laboratories, Inc. | Recombinase-based methods for producing expression vectors and compositions for use in practicing the same |
ATE463569T1 (de) | 1999-07-23 | 2010-04-15 | Univ California | Dna-rekombination in eukaryotischen zellen mittels des rekombinationszentrums vom bakteriophag phic31 |
ATE359819T1 (de) * | 2000-05-26 | 2007-05-15 | Symphogen As | Rekombinante oder gereinigte polyklonale antikörper zur behandlung den allergien |
US20040038392A1 (en) | 2000-06-08 | 2004-02-26 | Tatsurou Shibui | Expression vector enabling screening of cells with high expression of recombinant protein, transformant with high expression of recombinant protein and utilization thereof |
US6849259B2 (en) | 2000-06-16 | 2005-02-01 | Symphogen A/S | Polyclonal antibody composition for treating allergy |
US6610472B1 (en) * | 2000-10-31 | 2003-08-26 | Genetastix Corporation | Assembly and screening of highly complex and fully human antibody repertoire in yeast |
JP2004514444A (ja) * | 2000-11-28 | 2004-05-20 | アプライド モレキュラー エボリューション, インコーポレイテッド | 二重lox組換えに基づく真核生物発現ライブラリーおよび使用方法 |
US20030044398A1 (en) | 2001-03-20 | 2003-03-06 | Robl James M. | Methods for producing antibodies in mammals |
ES2442615T5 (es) | 2002-07-18 | 2023-03-16 | Merus Nv | Producción recombinante de mezclas de anticuerpos |
AU2003283995A1 (en) | 2002-09-30 | 2004-04-19 | Protein Design Labs, Inc. | Efficient generation of stable expression cell lines through the use of scorable homeostatic reporter genes |
PT1583830E (pt) | 2003-01-07 | 2006-11-30 | Symphogen As | Método para produzir proteínas policlonais recombinantes |
US20060275766A1 (en) | 2003-01-07 | 2006-12-07 | Haurum John S | Method for manufacturing recombinant polyclonal proteins |
TWI333977B (en) | 2003-09-18 | 2010-12-01 | Symphogen As | Method for linking sequences of interest |
WO2005070962A1 (en) | 2004-01-21 | 2005-08-04 | Novozymes A/S | Production of a monoclonal antibody in a heterokaryon fungus or in a fungal host cell |
AU2005263331B8 (en) | 2004-07-20 | 2011-06-16 | Symphogen A/S | Anti-Rhesus D recombinant polyclonal antibody and methods of manufacture |
KR101319848B1 (ko) | 2004-07-20 | 2013-10-18 | 심포젠 에이/에스 | 재조합 폴리클로날 단백질 또는 폴리클로날 세포주의구조적 특성화 방법 |
US7850965B2 (en) | 2005-12-05 | 2010-12-14 | Symphogen A/S | Anti-orthopoxvirus recombinant polyclonal antibody |
WO2007101441A1 (en) | 2006-03-06 | 2007-09-13 | Symphogen A/S | Recombinant polyclonal antibody for treatment of respiratory syncytial virus infections |
TW200846362A (en) | 2007-02-09 | 2008-12-01 | Symphogen As | A polyclonal antibody product |
JP5941616B2 (ja) | 2007-05-25 | 2016-06-29 | シムフォゲン・アクティーゼルスカブSymphogen A/S | 組み換えポリクローナルタンパク質を製造する方法 |
-
2004
- 2004-01-07 PT PT04700438T patent/PT1583830E/pt unknown
- 2004-01-07 AT AT04700438T patent/ATE338816T1/de active
- 2004-01-07 DK DK04700438T patent/DK1583830T3/da active
- 2004-01-07 SI SI200430074T patent/SI1583830T1/sl unknown
- 2004-01-07 EP EP04700438A patent/EP1583830B1/en not_active Expired - Lifetime
- 2004-01-07 ES ES04700438T patent/ES2273202T3/es not_active Expired - Lifetime
- 2004-01-07 MX MXPA05006724A patent/MXPA05006724A/es active IP Right Grant
- 2004-01-07 WO PCT/DK2004/000001 patent/WO2004061104A2/en active IP Right Grant
- 2004-01-07 CA CA2512647A patent/CA2512647C/en not_active Expired - Fee Related
- 2004-01-07 EP EP06018504A patent/EP1762617A1/en not_active Withdrawn
- 2004-01-07 EA EA200501101A patent/EA013225B1/ru not_active IP Right Cessation
- 2004-01-07 JP JP2006500508A patent/JP4589914B2/ja not_active Expired - Fee Related
- 2004-01-07 BR BR0406678-2A patent/BRPI0406678A/pt not_active Application Discontinuation
- 2004-01-07 NZ NZ541458A patent/NZ541458A/en not_active IP Right Cessation
- 2004-01-07 KR KR1020057012745A patent/KR101024443B1/ko not_active IP Right Cessation
- 2004-01-07 AU AU2004203727A patent/AU2004203727C1/en not_active Ceased
- 2004-01-07 DE DE602004002275T patent/DE602004002275T2/de not_active Expired - Lifetime
-
2005
- 2005-06-09 IL IL169101A patent/IL169101A/en not_active IP Right Cessation
- 2005-11-25 HK HK05110692A patent/HK1078896A1/xx not_active IP Right Cessation
-
2008
- 2008-12-19 US US12/339,490 patent/US9163232B2/en not_active Expired - Fee Related
-
2010
- 2010-07-08 JP JP2010155716A patent/JP2010268806A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
DE602004002275D1 (de) | 2006-10-19 |
AU2004203727A1 (en) | 2004-07-22 |
KR20050101538A (ko) | 2005-10-24 |
DE602004002275T2 (de) | 2007-09-06 |
PT1583830E (pt) | 2006-11-30 |
CA2512647A1 (en) | 2004-07-22 |
AU2004203727C1 (en) | 2008-08-21 |
US20090136498A1 (en) | 2009-05-28 |
WO2004061104A2 (en) | 2004-07-22 |
SI1583830T1 (sl) | 2006-12-31 |
ES2273202T3 (es) | 2007-05-01 |
CA2512647C (en) | 2013-10-08 |
JP4589914B2 (ja) | 2010-12-01 |
ATE338816T1 (de) | 2006-09-15 |
JP2010268806A (ja) | 2010-12-02 |
EA013225B1 (ru) | 2010-04-30 |
HK1078896A1 (en) | 2006-03-24 |
MXPA05006724A (es) | 2005-09-08 |
WO2004061104A3 (en) | 2004-11-04 |
JP2006515520A (ja) | 2006-06-01 |
EP1583830B1 (en) | 2006-09-06 |
EP1583830A2 (en) | 2005-10-12 |
KR101024443B1 (ko) | 2011-03-23 |
IL169101A (en) | 2009-02-11 |
NZ541458A (en) | 2006-04-28 |
AU2004203727B2 (en) | 2008-01-31 |
EA200501101A1 (ru) | 2006-02-24 |
DK1583830T3 (da) | 2007-01-15 |
US9163232B2 (en) | 2015-10-20 |
EP1762617A1 (en) | 2007-03-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0406678A (pt) | Método para produzir proteìnas policlonais recombinantes | |
EA200700249A1 (ru) | Рекомбинантное поликлональное антитело против резус-фактора d и способы его получения | |
DK2152872T3 (da) | Fremgangsmåde til fremstilling af et rekombinant polyklonalt protein | |
CN104854133B (zh) | 用于制备重组抗体治疗剂的最佳重链和轻链信号肽 | |
JP6573331B2 (ja) | 同起源の抗体可変領域遺伝子セグメントをクローニングおよび発現させるための迅速な方法 | |
CN104011080B (zh) | 用于真核细胞的全长抗体展示***及其用途 | |
BRPI0507433B8 (pt) | anticorpo monoclonal recombinante ou sua parte de ligação ao antígeno, composição, ácido nucleico isolado, vetor de expressão, e, kit | |
CN105602960A (zh) | 抗体的快速人源化 | |
Tchoudakova et al. | High level expression of functional human IgMs in human PER. C6® cells | |
Kurosawa et al. | Rapid production of antigen-specific monoclonal antibodies from a variety of animals | |
JP2006515503A5 (pt) | ||
DE60039596D1 (de) | Verfahren zur herstellung von monoklonalen antikörpern | |
PE20050376A1 (es) | Anticuerpos dirigidos a m-csf | |
ATE313633T1 (de) | Expressionsvektoren die für bispezifische proteine kodieren, und verfahren zur herstellung von biologisch-aktiven bispezifischen fusionsproteine in zellen von säugertieren | |
ATE498013T1 (de) | Für zellzyklusproteine kodierende nukleinsäure und deren verwendung | |
CN110494163A (zh) | 凝血因子viii模拟蛋白及其用途 | |
ES2440777T3 (es) | Vectores basados en anticuerpo anti-il-12, células huéspedes y métodos de producción y usos | |
Price et al. | Engineered cell surface expression of membrane immunoglobulin as a means to identify monoclonal antibody-secreting hybridomas | |
US20110008321A1 (en) | Vectors, Host Cells, and Methods of Production and Uses | |
ATE337395T1 (de) | Hybridomzelllinie g250 und deren verwendung zur herstellung monoklonaler antikörper | |
CN106478773A (zh) | 一种人工合成的新型信号肽 | |
ES2700442T3 (es) | Método para producir anticuerpos | |
CN106478774A (zh) | 一种用于蛋白质表达的信号肽 | |
CN104558180B (zh) | 靶向t淋巴细胞的人源单链抗体 | |
DE50015410D1 (de) | Nukleinsäuremolekül, umfassend eine für ein hämocyanin kodierende nukleinsäuresequenz und mindestens eine intronsequenz |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL |